You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIsoniazid
Accession NumberDB00951  (APRD01055, EXPT01940)
Typesmall molecule
Groupsapproved
Description

Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
4-pyridinecarbohydrazideNot AvailableNot Available
INHNot AvailableNot Available
IsoniazidNot AvailableNot Available
Isonicotinic acid hydrazideNot AvailableNot Available
Isonicotinic hydrazideNot AvailableNot Available
IsonicotinohydrazideNot AvailableNot Available
IsonicotinoylhydrazideNot AvailableNot Available
IsonicotinsaeurehydrazidNot AvailableNot Available
IsonicotinylhydrazineNot AvailableNot Available
Pyridine-4-carboxylic acid hydrazideNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
NicozidPiam
NidrazidZentiva
NydrazidSandoz
RimicidSopharma
RimifonRoche
ServizidNovartis
TibinideMeda
Brand mixtures
Brand NameIngredients
IsonaRifIsoniazid + Rifampicin
Isotamine B 300Isoniazid + Pyridoxine Hydrochloride
RifaterIsoniazid + Pyrazinamide + Rifampin
Categories
CAS number54-85-3
WeightAverage: 137.1393
Monoisotopic: 137.058911861
Chemical FormulaC6H7N3O
InChI KeyQRXWMOHMRWLFEY-UHFFFAOYSA-N
InChI
InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)
IUPAC Name
pyridine-4-carbohydrazide
SMILES
NNC(=O)C1=CC=NC=C1
Mass Specshow(8.21 KB)
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassPyridines and Derivatives
SubclassPyridinecarboxylic Acids and Derivatives
Direct parentPyridinecarboxylic Acids and Derivatives
Alternative parentsCarboxylic Acid Hydrazides; Enolates; Carboxylic Acid Amides; Polyamines; Hydrazines and Derivatives
Substituentscarboxamide group; carboxylic acid hydrazide; carboxylic acid derivative; enolate; polyamine; hydrazine derivative; amine; organonitrogen compound
Classification descriptionThis compound belongs to the pyridinecarboxylic acids and derivatives. These are compounds containing a pyridine ring bearing a carboxylic acid group or a derivative thereof.
Pharmacology
IndicationFor the treatment of all forms of tuberculosis in which organisms are susceptible.
PharmacodynamicsIsoniazid is a bactericidal agent active against organisms of the genus Mycobacterium, specifically M. tuberculosis, M. bovis and M. kansasii. It is a highly specific agent, ineffective against other microorganisms. Isoniazid is bactericidal to rapidly-dividing mycobacteria, but is bacteriostatic if the mycobacterium is slow-growing.
Mechanism of actionIsoniazid is a prodrug and must be activated by bacterial catalase. Specficially, activation is associated with reduction of the mycobacterial ferric KatG catalase-peroxidase by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex. Once activated, isoniazid inhibits the synthesis of mycoloic acids, an essential component of the bacterial cell wall. At therapeutic levels isoniazid is bacteriocidal against actively growing intracellular and extracellular Mycobacterium tuberculosis organisms. Specifically isoniazid inhibits InhA, the enoyl reductase from Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding competitive inhibitor of InhA.
AbsorptionReadily absorbed following oral administration; however, may undergo significant first pass metabolism. Absorption and bioavailability are reduced when isoniazid is administered with food.
Volume of distributionNot Available
Protein bindingVery low (0-10%)
Metabolism

Primarily hepatic. Isoniazid is acetylated by N -acetyl transferase to N -acetylisoniazid; it is then biotransformed to isonicotinic acid and monoacetylhydrazine. Monoacetylhydrazine is associated with hepatotoxicity via formation of a reactive intermediate metabolite when N-hydroxylated by the cytochrome P450 mixed oxidase system. The rate of acetylation is genetically determined. Slow acetylators are characterized by a relative lack of hepatic N -acetyltransferase.

Route of eliminationFrom 50 to 70 percent of a dose of isoniazid is excreted in the urine within 24 hours.
Half lifeFast acetylators: 0.5 to 1.6 hours. Slow acetylators: 2 to 5 hours.
ClearanceNot Available
ToxicityLD50 100 mg/kg (Human, oral). Adverse reactions include rash, abnormal liver function tests, hepatitis, peripheral neuropathy, mild central nervous system (CNS) effects. In vivo, Isoniazid reacts with pyridoxal to form a hydrazone, and thus inhibits generation of pyridoxal phosphate. Isoniazid also combines with pyridoxal phosphate; high doses interfere with the coenzyme function of the latter.
Affected organisms
  • Mycobacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Cytochrome P450 2E1
Gene symbol: CYP2E1
UniProt: P05181
rs6413419 CYP2E1 *1AG Allele, homozygoteHepatotoxicity16770646
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9892
Blood Brain Barrier + 0.9895
Caco-2 permeable + 0.6959
P-glycoprotein substrate Non-substrate 0.8315
P-glycoprotein inhibitor I Non-inhibitor 0.9778
P-glycoprotein inhibitor II Non-inhibitor 0.996
Renal organic cation transporter Non-inhibitor 0.9054
CYP450 2C9 substrate Non-substrate 0.9088
CYP450 2D6 substrate Non-substrate 0.9116
CYP450 3A4 substrate Non-substrate 0.7557
CYP450 1A2 substrate Inhibitor 0.6482
CYP450 2C9 substrate Non-inhibitor 0.9273
CYP450 2D6 substrate Non-inhibitor 0.9443
CYP450 2C19 substrate Non-inhibitor 0.9513
CYP450 3A4 substrate Non-inhibitor 0.5111
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9342
Ames test AMES toxic 0.8557
Carcinogenicity Non-carcinogens 0.7514
Biodegradation Not ready biodegradable 0.981
Rat acute toxicity 2.0713 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.9872
hERG inhibition (predictor II) Non-inhibitor 0.9586
Pharmacoeconomics
Manufacturers
  • Sandoz canada inc
  • Sandoz inc
  • Hoffmann la roche inc
  • Carolina medical products co
  • Mikart inc
  • Lannett co inc
  • Dow pharmaceutical corp sub dow chemical co
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Novartis pharmaceuticals corp
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Halsey drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Eli lilly and co
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Nexgen pharma inc
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Bristol myers squibb co
  • Everylife
Packagers
Dosage forms
FormRouteStrength
PowderOral
SyrupOral
TabletOral
Prices
Unit descriptionCostUnit
Isoniazid 100 mg/ml vial27.37USDml
Rifamate 150-300 mg capsule4.36USDcapsule
Rifamate capsule4.19USDcapsule
Isoniazid 100 mg tablet0.28USDtablet
Isoniazid 300 mg tablet0.18USDtablet
Isoniazid 50 mg/5ml Syrup0.16USDml
Isoniazid powder0.11USDg
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point171.4 °CPhysProp
water solubility1.4E+005 mg/L (at 25 °C)MERCK INDEX (2001)
logP-0.70HANSCH,C ET AL. (1995)
logS0.01ADME Research, USCD
pKa1.82 (at 20 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
water solubility3.49e+01 g/lALOGPS
logP-0.71ALOGPS
logP-0.69ChemAxon
logS-0.59ALOGPS
pKa (strongest acidic)13.61ChemAxon
pKa (strongest basic)3.35ChemAxon
physiological charge0ChemAxon
hydrogen acceptor count3ChemAxon
hydrogen donor count2ChemAxon
polar surface area68.01ChemAxon
rotatable bond count1ChemAxon
refractivity37.46ChemAxon
polarizability13.21ChemAxon
number of rings1ChemAxon
bioavailability1ChemAxon
rule of fiveYesChemAxon
Ghose filterNoChemAxon
Veber's ruleNoChemAxon
MDDR-like ruleNoChemAxon
Spectra
SpectraNot Available
References
Synthesis Reference

Costin Rentzea, Albrecht Harreus, Eberhard Ammermann, Gisela Lorenz, “Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides.” U.S. Patent US5399589, issued November, 1969.

US5399589
General ReferenceNot Available
External Links
ResourceLink
KEGG DrugD00346
KEGG CompoundC07054
PubChem Compound3767
PubChem Substance46506039
ChemSpider3635
ChEBI6030
ChEMBLCHEMBL64
Therapeutic Targets DatabaseDAP000011
PharmGKBPA450112
HETISZ
Drug Product Database577782
RxListhttp://www.rxlist.com/cgi/generic2/isoniaz.htm
Drugs.comhttp://www.drugs.com/cdi/isoniazid.html
WikipediaIsoniazid
ATC CodesJ04AC01
AHFS Codes
  • 08:16.04
PDB EntriesNot Available
FDA labelNot Available
MSDSshow(73.1 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolIsoniazid may increase the anticoagulant effect of acenocoumarol.
AcetaminophenRisk of hepatotoxicity
AminophyllineIsoniazid may increase the effect and toxicity of oxtriphylline.
AnisindioneIsoniazid may increase the anticoagulant effect of anisindione.
BromazepamIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of bromazepam by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of bromazepam if isoniazid is initiated, discontinued or dose changed. Dosage adjustments may be required.
CarbamazepineCarbamazepine effect is increased as is isoniazid toxicity
CarisoprodolStrong CYP2C19 inhibitors such as isoniazid may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased.
DantroleneIsoniazid may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if isoniazid is initiated, discontinued or dose changed.
DicoumarolIsoniazid may increase the anticoagulant effect of dicumarol.
DisulfiramIncreased risk of CNS adverse effects
DyphyllineIncreases the effect and toxicity of theophylline
EltrombopagAffects hepatic CYP1A2 metabolism, increases Eltrombopag level or affect.
EthotoinIsoniazid increases the effect of phenytoin in 20% of patients
FosphenytoinIsoniazid may increase the effect of phenytoin in 20% of patients.
KetoconazoleIsoniazid decreases the effect of ketoconazole
MephenytoinIsoniazid increases the effect of phenytoin in 20% of patients
OxtriphyllineIsoniazid may increase the effect and toxicity of oxtriphylline.
PethidinePossible episodes of hypotension
PhenytoinIsoniazid increases the effect of phenytoin in 20% of patients
TacrolimusThe strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tacrolimus, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Tacrolimus if Isoniazid is initiated, discontinued or dose changed.
TadalafilIsoniazid may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
TamoxifenIsoniazid may increase the serum concentration of Tamoxifen by decreasing its metabolism and clearance. Isoniazid may also decrease the therapeutic effect of Tamoxifen by decreasing active metabolite production. Monitor for changes in the therapeutic/adverse effects of Tamoxifen if Isoniazid is initiated, discontinued or dose changed.
TamsulosinIsoniazid, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Isoniazid is initiated, discontinued, or dose changed.
TelithromycinIsoniazid may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
TemsirolimusIsoniazid may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
TeniposideThe strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Isoniazid is initiated, discontinued or dose changed.
TheophyllineIsoniazid may increase the therapeutic and adverse effects of theophylline.
TiagabineThe strong CYP3A4 inhibitor, Isoniazid, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Isoniazid is initiated, discontinued or dose changed.
TolterodineIsoniazid may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
TramadolIsoniazid may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Isoniazid may decrease the effect of Tramadol by decreasing active metabolite production.
TrazodoneThe CYP3A4 inhibitor, Isoniazid, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Isoniazid is initiated, discontinued or dose changed.
TrimipramineThe strong CYP3A4/CYP2C19 inhibitor, Isoniazide, may decrease the metabolism and clearance of Trimipramine, a CYP3A4/CYP2C19 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Isoniazid is initiated, discontinued or dose changed.
VardenafilIsoniazid, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil.
VenlafaxineIsoniazid, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Isoniazid is initiated, discontinued, or dose changed.
VerapamilIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Isoniazid is initiated, discontinued or dose changed.
VinblastineIsoniazid, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Isoniazid is initiated, discontinued or dose changed.
VincristineIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Isoniazid is initiated, discontinued or dose changed.
VinorelbineIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Isoniazid is initiated, discontinued or dose changed.
WarfarinIsoniazid may increase the anticoagulant effect of warfarin.
ZolpidemIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if isoniazid is initiated, discontinued or dose changed.
ZonisamideIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if isoniazid is initiated, discontinued or dose changed.
ZopicloneIsoniazid, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if isoniazid is initiated, discontinued or dose changed.
Food Interactions
  • Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
  • Avoid alcohol.
  • Do not take calcium, aluminum, magnesium or Iron supplements within 2 hours of taking this medication.
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

Targets

1. Catalase-peroxidase

Kind: protein

Organism: Mycobacterium tuberculosis

Pharmacological action: yes

Actions: other/unknown

Components

Name UniProt ID Details
Catalase-peroxidase Q08129 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Pym AS, Domenech P, Honore N, Song J, Deretic V, Cole ST: Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. Mol Microbiol. 2001 May;40(4):879-89. Pubmed
  4. Heym B, Alzari PM, Honore N, Cole ST: Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995 Jan;15(2):235-45. Pubmed
  5. Wilson TM, de Lisle GW, Collins DM: Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol. 1995 Mar;15(6):1009-15. Pubmed
  6. Vilcheze C, Jacobs WR Jr: The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007;61:35-50. Pubmed

2. Enoyl-[acyl-carrier-protein] reductase [NADH]

Kind: protein

Organism: Mycobacterium tuberculosis

Pharmacological action: yes

Actions: adduct

Components

Name UniProt ID Details
Enoyl-[acyl-carrier-protein] reductase [NADH] P0A5Y6 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Schroeder EK, Basso LA, Santos DS, de Souza ON: Molecular dynamics simulation studies of the wild-type, I21V, and I16T mutants of isoniazid-resistant Mycobacterium tuberculosis enoyl reductase (InhA) in complex with NADH: toward the understanding of NADH-InhA different affinities. Biophys J. 2005 Aug;89(2):876-84. Epub 2005 May 20. Pubmed
  4. Wilson TM, de Lisle GW, Collins DM: Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol. 1995 Mar;15(6):1009-15. Pubmed
  5. Broussy S, Coppel Y, Nguyen M, Bernadou J, Meunier B: 1H and 13C NMR characterization of hemiamidal isoniazid-NAD adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis. Chemistry. 2003 May 9;9(9):2034-8. Pubmed
  6. Vilcheze C, Jacobs WR Jr: The mechanism of isoniazid killing: clarity through the scope of genetics. Annu Rev Microbiol. 2007;61:35-50. Pubmed
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2E1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 2E1 P05181 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

7. Arylamine N-acetyltransferase 2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Arylamine N-acetyltransferase 2 P11245 Details

References:

  1. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, van Helden PV, Sim E: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol. 2001 Oct;42(2):309-17. Pubmed

8. Arylamine N-acetyltransferase

Kind: protein

Organism: Mycobacterium tuberculosis

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Arylamine N-acetyltransferase P0A5L8 Details

References:

  1. Upton AM, Mushtaq A, Victor TC, Sampson SL, Sandy J, Smith DM, van Helden PV, Sim E: Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol Microbiol. 2001 Oct;42(2):309-17. Pubmed

9. Cytochrome P450 2A6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2A6 P11509 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:12